Teva sues Corcept over mifepristone 'monopoly' for rare disorder
By Mike Scarcella
June 13 (Reuters) -Teva Pharmaceuticals TEVA.TA sued rival drugmaker Corcept Therapeutics CORT.O in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-basedKorlym, used to treat a rare hormonal disorder called Cushing's syndrome.
The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
Korlym's active ingredient is mifepristone, the same drug used for medication abortion at the center of Thursday’s U.S. Supreme Court ruling that rejected a legal challenge seeking to curtail access to the drug for terminating pregnancies.
Teva's antitrust lawsuit, which does not refer to the drug's use for abortion, said Corcept and Optime have a long-term exclusive-dealing arrangement that bars Optime from distributing any medication that competes with Korlym.
Corcept and Optime did not immediately respond to requests for comment on Thursday.
Teva in a statement said that Corcept's anticompetitive conduct "has prevented patients with Cushing’s syndrome from accessing lower-cost generics to treat their debilitating disease.”
Cushing’s, caused by too much of the hormone cortisol in the body, affects about 20,000 people in the United States and can be fatal, the lawsuit said. Symptoms include abnormal weight gain and a fatty hump between the shoulders.
Teva said it launched its generic version of Korlym five months ago, but “during that time Teva has captured close to zero market share.”
The lawsuit said Teva has tried to convince Optime to distribute Teva's generic Korlym, but Optime has refused.
"Optime’s representatives made clear that there was nothing Teva could do to gain access to the Optime distribution channel," according to the lawsuit.
Teva accused Corcept of artificially inflating the cost of Korlym based on the company’s market power. The lawsuit said a year’s supply of the drug can be “several hundred thousand dollars or more.”
Corcept sued Teva in 2018 in New Jersey federal court for allegedly infringing on Korlym patents. A judge ruled for Teva last year, and Corcept has appealed.
Reporting by Mike Scarcella
Editing by David Bario and Rod Nickel
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
